Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 16 de 16
Filter
1.
Nat Mater ; 18(8): 816-819, 2019 Aug.
Article in English | MEDLINE | ID: mdl-31036961

ABSTRACT

Superconducting quantum information processing machines are predominantly based on microwave circuits with relatively low characteristic impedance, about 100 Ω, and small anharmonicity, which can limit their coherence and logic gate fidelity1,2. A promising alternative is circuits based on so-called superinductors3-6, with characteristic impedances exceeding the resistance quantum RQ = 6.4 kΩ. However, previous implementations of superinductors, consisting of mesoscopic Josephson junction arrays7,8, can introduce unintended nonlinearity or parasitic resonant modes in the qubit vicinity, degrading its coherence. Here, we present a fluxonium qubit design based on a granular aluminium superinductor strip9-11. We show that granular aluminium can form an effective junction array with high kinetic inductance and be in situ integrated with standard aluminium circuit processing. The measured qubit coherence time [Formula: see text] illustrates the potential of granular aluminium for applications ranging from protected qubit designs to quantum-limited amplifiers and detectors.

2.
Nat Methods ; 14(11): 1087-1089, 2017 Nov.
Article in English | MEDLINE | ID: mdl-29039418

ABSTRACT

Image scanning microscopy (ISM) doubles the resolution of a conventional confocal microscope for super-resolution imaging. Here, we describe an all-optical ISM design based on rescanning microscopy for two-photon-excited fluorescence and second-harmonic generation that allows straightforward implementation into existing microscopes. The design offers improved sensitivity and high frame rates relative to those of existing systems. We demonstrate its utility using fixed and living specimens as well as collagen hydrogels.


Subject(s)
Microscopy, Confocal/methods , Microscopy, Fluorescence/methods , Animals , Cells, Cultured , Drosophila melanogaster/embryology , Humans , Mesenchymal Stem Cells/cytology , Signal-To-Noise Ratio
3.
Springerplus ; 5: 373, 2016.
Article in English | MEDLINE | ID: mdl-27066381

ABSTRACT

BACKGROUND: Paclitaxel-coated balloon (PCB) angioplasty in small vessel de novo lesions has favourable outcome and appears to be an alternative to stent implantation. However there is limitted data on its use specifically in small vessel acute coronary syndrome (ACS). METHODS: We analyse patients data from the SeQuent Please Small Vessel 'PCB only' Registry. It was an international, prospective, multicentre registry which enrolled patients with de novo lesions of small vessel diameter (≥2.0, ≤2.75 mm). Patients were divided into the ACS group and the non-ACS group and comparison made between the two groups. The primary end-point was clinically driven target lesion revascularisation (TLR) at 9 months. Secondary end-points were acute technical success, 30-day and 9-month major adverse cardiac events (death, myocardial infarction or TLR) (MACE) and the occurence of definite lesion and vessel thrombosis. RESULTS: A total of 447 patients were enrolled for this registry of which 105 (23.5 %) patients were ACS (STEMI and NSTEMI). The procedural success rate was 98.1 % in ACS group. The mean vessel diameter for the ACS and non-ACS group were 2.15 ± 0.36 and 2.14 ± 0.35 respectively. Similar mean lesion length of around 15.5 mm was recorded in both groups. Additional stenting was required in 9.3 % ACS and 6.5 % non-ACS, p = 0.308. Reasons for additional stenting were target lesion related dissection (57.6 %) or non-target lesion stenosis (41.2 %). More than half of the patients had 4 weeks of aspirin/clopidogrel (57.1 % ACS, 60.5 % non-ACS). No significant difference between the ACS and non-ACS groups with regards to the duration and types of DAPT during follow up. At 30-day, MACE rate were (0 % ACS vs 0.3 % non-ACS, p = 0.599). At 9 months TLR rates were (1.2 % ACS vs 4.3 % non-ACS, p = 0.180) and MACE rates (3.6 % ACS vs 5.0 % non-ACS, p = 0.601). CONCLUSION: PCB in ACS with small vessel de novo lesions has low 30-day and 9-month TLR/MACE rates comparable to non-ACS small vessels. Thus it appears to be an alternative to stent implantation in the treatment ACS.

4.
BMC Cardiovasc Disord ; 8: 41, 2008 Dec 23.
Article in English | MEDLINE | ID: mdl-19105833

ABSTRACT

BACKGROUND: Cytochrome P450 (CYP) enzyme 2J2, an epoxygenase predominantly expressed in the heart, metabolizes arachidonic acid to biologically active eicosanoids. One of the CYP2J2 products, 11, 12-epoxyeicosatrienoic acid, has several vasoprotective effects. The CYP2J2-G-50T-promotor polymorphism decreases gene expression and is associated with coronary artery disease. This association supports the vascular protective role of CYP-derived eicosanoids in cardiovascular disease. In the present study, we investigated the influence of this polymorphism on survived myocardial infarction in two study groups of patients with on average high cardiovascular risk profile. METHODS: The CYP2J2 polymorphism was genotyped in two groups of patients that were collected with the same method of clinical data collection. Data from 512 patients with sleep apnoea (group: OSA) and on average high cardiovascular risk profile and from another 488 patients who were admitted for coronary angiography (CAR-group) were evaluated for a potential correlation of the CYP2J2 polymorphism G-50T and a history of myocardial infarction. The G-50T polymorphism of the CYP2J2 gene was genotyped by allele specific restriction and light cycler analysis. RESULTS: The T-allele of the polymorphism was found in 111 (11.1%; CAR-group: N = 65, 13.3%; OSA: N = 46, 9.0%). 146 patients had a history of myocardial infarction (CAR: N = 120, 24.6%; OSA: N = 26, 5.1%). Cardiovascular risk factors were equally distributed between the different genotypes of the CYP2J2 G-50T polymorphism. In the total group of 1000 individuals, carriers of the T-allele had significantly more myocardial infarctions compared to carriers of the wild type (T/T or G/T: 21.6%; G/G: 13.7%; p = 0.026, odds ratio 1.73, 95%-CI [1.06-2.83]). In the multivariate logistic regression analysis the odds ratio for a history of myocardial infarction in carriers of the T-allele was 1.611, 95%-CI [0.957-2.731] but this trend was not significant (p = 0.073). CONCLUSION: In presence of other risk factors, the CYP2J2 G-50T failed to show a significant role in the development of myocardial infarction. However, since our result is close to the border of significance, this question should be clarified in larger, prospective studies in the future.


Subject(s)
Cytochrome P-450 Enzyme System/genetics , Genetic Predisposition to Disease , Myocardial Infarction/genetics , Myocardium/enzymology , Aged , Cytochrome P-450 CYP2J2 , Cytochrome P-450 Enzyme System/metabolism , DNA Mutational Analysis , Female , Germany , Humans , Male , Middle Aged , Myocardial Infarction/epidemiology , Odds Ratio , Polymorphism, Single Nucleotide , Risk Factors
5.
Int J Cardiol ; 120(2): 254-61, 2007 Aug 21.
Article in English | MEDLINE | ID: mdl-17346818

ABSTRACT

BACKGROUND: Decisions for coronary revascularisation are frequently based on visual assessment of the severity of a stenosis. In patients with intermediate left main stem lesions clinical decision making based on FFR is safe and feasible. This study was performed to assess the accuracy of visual angiographic assessment of intermediate or equivocal left main coronary artery (LMCA) stenoses by experienced interventional cardiologists when taking fractional flow reserve (FFR) measurements as the gold standard. METHODS: Fifty-one patients with intermediate (40-80% diameter stenosis by angiography) or equivocal LMCA disease were evaluated by FFR. Angiograms were then reviewed by 4 experienced interventionalists from different university hospitals blinded to FFR results. Lesions were visually assessed and their significance classified as 'significant', 'not significant', or 'unsure' if the observer was unable to make a decision regarding lesion significance based on the angiogram. RESULTS: Results were compared with two different FFR cutoff values (< 0.75 and < or = 0.80) for hemodynamic significance. The 4 reviewers achieved correct lesion classification in no more than approximately 50% of cases each, regardless of FFR threshold. The interobserver agreement between two reviewers in excess of the agreement expected due to chance was outperformed on average by only 16%. Furthermore, interobserver variability was large resulting in unanimously correct lesion classification in only 29% of all cases. CONCLUSIONS: The functional significance of intermediate and equivocal LMCA stenoses should not be based solely on angiographic assessment even by experienced interventional cardiologists.


Subject(s)
Blood Flow Velocity/physiology , Blood Pressure/physiology , Cardiology/standards , Clinical Competence , Coronary Stenosis/diagnosis , Coronary Vessels/physiopathology , Coronary Angiography , Coronary Stenosis/physiopathology , Female , Humans , Male , Middle Aged , Observer Variation , Prognosis , Severity of Illness Index
6.
Trends Cardiovasc Med ; 16(6): 204-8, 2006 Aug.
Article in English | MEDLINE | ID: mdl-16839864

ABSTRACT

Cytochrome P450 (CYP) enzyme 2J2, an epoxygenase predominantly expressed in the heart, metabolizes arachidonic acid to biologically active eicosanoids. One of the CYP2J2 products, 11,12-epoxyeicosatrienoic acid, has several vasoprotective effects. A frequent promoter polymorphism of CYP2J2 decreases gene expression and is associated with coronary artery disease. This association supports the vascular protective role of CYP-derived eicosanoids in cardiovascular disease.


Subject(s)
Coronary Artery Disease/enzymology , Cytochrome P-450 Enzyme System/biosynthesis , Oxygenases/biosynthesis , Coronary Artery Disease/genetics , Cytochrome P-450 CYP2J2 , Cytochrome P-450 Enzyme System/genetics , Eicosanoids/biosynthesis , Endothelium, Vascular/metabolism , Gene Expression Regulation , Humans , Oxygenases/genetics , Polymorphism, Genetic , Promoter Regions, Genetic/genetics , Risk Factors
7.
Exp Gerontol ; 41(5): 549-51, 2006 May.
Article in English | MEDLINE | ID: mdl-16621389

ABSTRACT

Several structural and functional changes contribute to heart failure in elderly patients: an age dependent increase in sympathetic nervous activity, left ventricular wall diameter, myocardial fibrosis and apoptosis, micro- and macrovascular coronary sclerosis, aortic stiffness. As a consequence, diastolic, but also systolic heart failure is a frequent finding in elderly patients. The relation of systolic to diastolic heart failure is clearly shifted towards diastolic heart failure in elderly patients, especially in women. Mortality is increased with systolic dysfunction in elderly patients compared to younger heart failure patients. Mortality is less with diastolic dysfunction, but still higher compared to elderly without heart failure. In addition, morbidity is increased both with diastolic and systolic heart failure in elderly patients. Cognitive dysfunction is a frequent finding. After exclusion of specific cardiac and extracardiac reasons for dyspnoea, drug therapy of systolic heart failure in elderly is similar to younger patients. However, the physiological decrease of renal function and the more frequent renal impairment in elderly patients with heart failure needs to be considered. Guideline recommendations for drug therapy are based in most cases on studies conducted in younger systolic heart failure patients. A recent meta-analysis of randomized beta-blocker trials suggests improved survival with beta-blockers even in the elderly subgroup. Guidelines for the treatment of diastolic heart failure are available only recently. The term heart failure with normal left ventricular ejection fraction (LVEF) has been proposed instead of diastolic heart failure. Given the increased morbidity and mortality in elderly patients with heart failure and normal LVEF, therapy should include general measures, such as physical activity, weight reduction, volume restriction. Specific therapy includes optimal control of systolic and diastolic blood pressure, diuretics, nitrates, and frequency-control. However, randomized trials evaluating the efficacy of specific therapies in heart failure with normal LVEF are still missing.


Subject(s)
Heart Failure/therapy , Adrenergic beta-Antagonists/therapeutic use , Aged , Diastole , Female , Heart Failure/diagnosis , Heart Failure/epidemiology , Heart Failure/physiopathology , Humans , Male , Prognosis , Systole
8.
Int J Cardiol ; 113(2): 161-6, 2006 Nov 10.
Article in English | MEDLINE | ID: mdl-16330115

ABSTRACT

BACKGROUND: Cardioversion for atrial fibrillation (AF) is associated with impairment of left atrial mechanical function and increased risk of thrombus formation with subsequent embolisation. Measuring atrial mechanical function is of interest to determine the individual risk of thromboembolism and the risk of recurrent AF. METHODS: We included 112 consecutive patients with AF and planned cardioversion. Serial echocardiographic measurements of left atrial size and Doppler measurement of mitral valve peak A wave velocities were obtained at days 0, 1, 2, 3, and 28 following cardioversion. These measurements and clinical parameters were related to clinical events and recurrent AF within 4 weeks following cardioversion. Cardioversion was achieved in 100 patients. RESULTS: AF-recurrence within 4 weeks was 23.9% and 45.8% for patients with < or = and > 6 weeks AF-duration, respectively (p=0.04). Peak A wave velocities were significantly lower up to 2 days following cardioversion in patients with AF-recurrence. A peak A wave velocity < 52 cm/s at day 1 resulted in an odds ratio of 5.0 (95% CI: 1.4-18.6) for recurrence of AF. In multiple logistic regression analysis, peak A wave velocity at day 1 remained the only independent predictor of recurrent AF. Left atrial diameter did not correlate with recurrence of AF. CONCLUSIONS: A single measurement of mitral peak A wave velocity 1 day following cardioversion is predictive of AF recurrence. This method is feasible for risk estimation with potential therapeutic implications.


Subject(s)
Atrial Fibrillation/diagnostic imaging , Atrial Fibrillation/therapy , Echocardiography, Doppler/methods , Electric Countershock/methods , Atrial Fibrillation/physiopathology , Blood Flow Velocity , Feasibility Studies , Female , Follow-Up Studies , Humans , Male , Middle Aged , Prognosis , Recurrence
10.
Arch Biochem Biophys ; 433(2): 413-20, 2005 Jan 15.
Article in English | MEDLINE | ID: mdl-15581597

ABSTRACT

Cytochrome P450 epoxygenases metabolize arachidonic acid to biologically active eicosanoids. Primary epoxidation products are four regioisomers of cis-epoxyeicosatrienoic acid (EET), 5,6-, 8,9-, 11,12-, and 14,15-EET. One of the predominant epoxygenase isoforms involved in EET formation belongs to the CYP2 gene family. In humans, the P450 epoxygenase, CYP2J2, is expressed in the cardiovascular system, namely the endothelium, vascular smooth muscle, and cardiomyocyte. CYP2J2 possesses vascular protective effects, which include but are not limited to, protection against ischemia-reperfusion injury, suppression of reactive oxygen species following hypoxia-reoxygenation, inhibition of the pro-inflammatory transcription factor, nuclear factor-kappaB (NF-kappaB), attenuation of vascular smooth muscle migration, and enhancement of a fibrinolytic pathway. Although regioisomers of EET elicit these effects to varying degrees, 11,12-EET appears to be the most potent with respect to anti-inflammatory, anti-migratory, and pro-fibrinolytic effects. Thus, CYP2J2 and its derived arachidonic acid metabolites may play important roles in regulating vascular function under normal and pathophysiological conditions.


Subject(s)
8,11,14-Eicosatrienoic Acid/analogs & derivatives , Cytochrome P-450 Enzyme System/metabolism , Eicosanoids/pharmacology , Oxygenases/metabolism , Protective Agents/pharmacology , 8,11,14-Eicosatrienoic Acid/metabolism , 8,11,14-Eicosatrienoic Acid/pharmacology , Animals , Arachidonic Acid/metabolism , Cell Movement/drug effects , Cytochrome P-450 CYP2J2 , Eicosanoids/metabolism , Fibrinolysis/drug effects , Humans , Inflammation/drug therapy , Isoenzymes/metabolism , Isoenzymes/pharmacology , Models, Biological , Muscle, Smooth, Vascular/drug effects , Muscle, Smooth, Vascular/metabolism , Myocytes, Cardiac/drug effects , Myocytes, Cardiac/metabolism , NF-kappa B/drug effects , Protective Agents/metabolism , Stereoisomerism , Vasodilation/drug effects
11.
Circulation ; 110(15): 2132-6, 2004 Oct 12.
Article in English | MEDLINE | ID: mdl-15466638

ABSTRACT

BACKGROUND: Cytochrome P450 (CYP) 2J2 is expressed in the vascular endothelium and metabolizes arachidonic acid to biologically active epoxyeicosatrienoic acids (EETs). The EETs are potent endogenous vasodilators and inhibitors of vascular inflammation. However, it is not known whether genetic polymorphisms of CYP2J2 are associated with increased cardiovascular risks. METHODS AND RESULTS: All 9 exons of the CYP2J2 gene and its proximal promoter were sequenced in 132 patients to identify potential variants. Functional consequence of a single nucleotide polymorphism (SNP) in the promoter of CYP2J2 was further evaluated by use of transcription factor-binding and reporter assays. A total of 17 polymorphisms were identified. One of the most relevant polymorphisms in terms of frequency and functional importance is located at -50 (G-50T) in the proximal promoter of CYP2J2. Screening of 289 patients with coronary artery disease and 255 control subjects revealed 77 individuals with the G-50T SNP (17.3% of coronary artery disease patients, 10.6% of control subjects; P=0.026). The association of the G-50T polymorphism remained significant after adjustment for age, gender, and conventional cardiovascular risk factors (OR, 2.23; 95% CI, 1.04 to 4.79). The G-50T mutation resulted in the loss of binding of the Sp1 transcription factor to the CYP2J2 promoter and resulted in a 48.1+/-2.4% decrease in CYP2J2 promoter activity (P<0.01). Plasma concentrations of stable EET metabolites were significantly lower in individuals with the G-50T SNP. CONCLUSIONS: A functionally relevant polymorphism of the CYP2J2 gene is independently associated with an increased risk of coronary artery disease.


Subject(s)
Coronary Disease/genetics , Cytochrome P-450 Enzyme System/genetics , Oxygenases/genetics , Polymorphism, Single Nucleotide , Promoter Regions, Genetic/genetics , 3' Untranslated Regions/genetics , 8,11,14-Eicosatrienoic Acid/analogs & derivatives , Aged , Amino Acid Substitution , Arachidonic Acid/metabolism , Base Sequence , Binding Sites/genetics , Coronary Disease/epidemiology , Cytochrome P-450 CYP2J2 , Cytochrome P-450 Enzyme System/physiology , DNA Mutational Analysis , Eicosanoids/biosynthesis , Exons/genetics , Female , Genetic Testing , Genotype , Germany/epidemiology , Humans , Hydroxyeicosatetraenoic Acids/blood , Introns/genetics , Male , Middle Aged , Molecular Sequence Data , Oxygenases/physiology , Risk , Sequence Analysis, DNA , Sp1 Transcription Factor/metabolism
12.
Chest ; 126(3): 935-41, 2004 Sep.
Article in English | MEDLINE | ID: mdl-15364776

ABSTRACT

STUDY OBJECTIVES: To assess the practical application and safety of prehospital antithrombotic therapy with the glycoprotein (GP) IIb/IIIa inhibitor eptifibatide for patients with suspected acute coronary syndrome (ACS) or myocardial infarction (MI). DESIGN: Open-labeled pilot study. Patients with typical chest pain who were seen within 6 h of the onset of symptoms were enrolled in the mobile emergency ambulance. Patients were stratified by even/uneven days to receive standard treatment or standard treatment plus an IV bolus of eptifibatide (180 microg/kg body weight) followed by a continuous eptifibatide infusion (2 microg/kg/min). The main outcome measurement was a combination of prehospital or in-hospital death, reinfarction, revascularization of target vessels, and major bleeding complications. RESULTS: A total of 356 patients (age range, 29 to 75 years; women, 24.7%) were included in the analysis. On admission to the hospital, the diagnosis of ACS or MI was confirmed in approximately 60% of patients, and alternative diagnoses were made in 40% of patients. The rates of complications, including fatal and nonfatal complications occurring during transportation and during subsequent hospitalization, were similar in both study groups. The primary end point occurred in 11.8% of patients in the control group, and in 9.6% of those in the eptifibatide group (difference not significant). CONCLUSION: The prehospital administration of the GP IIb/IIIa inhibitor eptifibatide is feasible and safe in patients with clinically suspected ACS and MI. The benefit of this treatment has yet to be established in a large-scale multicenter study.


Subject(s)
Coronary Thrombosis/drug therapy , Emergency Medical Services , Myocardial Infarction/drug therapy , Peptides/administration & dosage , Platelet Aggregation Inhibitors/administration & dosage , Platelet Glycoprotein GPIIb-IIIa Complex/antagonists & inhibitors , Aged , Ambulances , Berlin , Coronary Thrombosis/blood , Coronary Thrombosis/mortality , Eptifibatide , Feasibility Studies , Female , Hospital Mortality , Humans , Infusions, Intravenous , Male , Middle Aged , Myocardial Infarction/blood , Myocardial Infarction/mortality , Outcome Assessment, Health Care , Peptides/adverse effects , Pilot Projects , Platelet Aggregation Inhibitors/adverse effects , Survival Analysis
13.
Eur Heart J ; 24(19): 1744-9, 2003 Oct.
Article in English | MEDLINE | ID: mdl-14522569

ABSTRACT

AIMS: Clopidogrel is a pro-drug which is converted to an active, unstable drug by cytochrome P450 (CYP). The active drug irreversibly blocks one specific platelet adenosine 5'-diphosphate (ADP) receptor (P2Y12). It has been recently suggested that the most abundant human CYP isoform, 3A4, activates clopidogrel. Since certain lipophilic statins (i.e. simvastatin, atorvastatin, lovastatin) are a substrate of CYP3A4, we were interested in potential drug interactions between clopidogrel and statins. METHODS: In patients with coronary artery disease (n=47) in whom clopidogrel treatment was initiated for balloon angioplasty and stent implantation, blood samples were taken at 0, 5 and 48 h after oral administration of clopidogrel (loading dose 300 mg, followed by 75 mg daily). ADP-stimulated (1, 10, 100 micromol/l) expression of P-selectin (CD62P) on platelets was measured by flow cytometry, and used as a marker for the antiplatelet effect of clopidogrel. RESULTS: Pre-treatment with statins (atorvastatin, simvastatin) reduced significantly (10 micromol/l ADP stimulation) the inhibitory effects of clopidogrel during the loading phase (relative reduction after 5 h 29.3%) and, to a lesser extent during the maintenance phase (relative reduction after 48 h 16.6%). In addition we found a considerable individual heterogeneity in the response and three patients (6%) were identified in whom clopidogrel exerted almost no effect. CONCLUSION: Certain statins which are substrates of the CYP3A4 isoform competitively inhibit the metabolic activation of clopidogrel. As a result the relative clopidogrel induced platelet inhibition (P-selectin-expression) is diminished--but still there is a relative clopidogrel effect of more than 80% in the maintenance phase. It may be reasonable to test the therapeutic efficacy of clopidogrel in those patients who require long-term treatment.


Subject(s)
Blood Platelets/drug effects , Coronary Disease/therapy , Hydroxymethylglutaryl-CoA Reductase Inhibitors/pharmacology , Platelet Aggregation Inhibitors/pharmacology , Ticlopidine/analogs & derivatives , Ticlopidine/pharmacology , Aged , Angioplasty, Balloon, Coronary , Blood Platelets/metabolism , Clopidogrel , Cytochrome P-450 CYP3A , Cytochrome P-450 Enzyme System/metabolism , Drug Interactions , Female , Flow Cytometry , Humans , Male , P-Selectin/metabolism , Prospective Studies , Stents , Time Factors
14.
Mol Pharmacol ; 62(4): 856-63, 2002 Oct.
Article in English | MEDLINE | ID: mdl-12237332

ABSTRACT

Tranilast [N-(3,4-dimethoxycinnamoyl)anthranilic acid] inhibits vascular inflammation. However, the relevant anti-inflammatory mechanisms are not completely understood. We studied the effects of tranilast on nuclear factor-kappaB (NF-kappaB)-dependent endothelial cell adhesion molecule expression and transcriptional regulation. Cultured human umbilical vein endothelial cells were preincubated with 12.5 to 100 microg/ml tranilast. Tumor necrosis factor-alpha (TNF-alpha)-induced endothelial VCAM-1, ICAM-1, and E-selectin surface expression was inhibited dose dependently. Maximal inhibition achieved with 100 microg/ml tranilast was 38 +/- 6.9, 31.8 +/- 1.5, and 31.9 +/- 1.9%, respectively (mean +/- S.E.M., p < 0.001, n = 5). Secretion of interleukin 6, which is also NF-kappaB-sensitive, was significantly inhibited by tranilast. Endothelial MHC-I expression, which is independent of NF-kappaB, was not inhibited. Although cytokine-induced degradation of NF-kappaB inhibitor proteins (IkappaB-alpha, -beta, and -epsilon), nuclear translocation of NF-kappaB, and binding of NF-kappaB to kappaB cis-acting elements in the adhesion molecule promoters were not affected by tranilast, ICAM-1-kappaB and E-selectin-kappaB reporter gene activity was inhibited by 53% (n = 5, p < 0.01) and 51% (n = 5, p < 0.001), respectively. In contrast, using SP-1 and C/EBP constructs, reporter gene activity was not altered. Expression of the transcriptional coactivator cAMP response element binding protein binding protein (CBP) was inhibited by tranilast, resulting in a loss of interaction between NF-kappaB and CBP. Therefore, in therapeutically relevant concentrations (50 microg/ml), tranilast inhibits NF-kappaB-dependent transcriptional activation by interfering with the NF-kappaB/CBP association. We propose that inhibition of NF-kappaB dependent gene transcription contributes to the anti-inflammatory effects of tranilast.


Subject(s)
Cytokines/pharmacology , DNA-Binding Proteins , Endothelium, Vascular/drug effects , NF-kappa B/metabolism , ortho-Aminobenzoates/pharmacology , Activating Transcription Factor 1 , Active Transport, Cell Nucleus/drug effects , Cell Adhesion Molecules/metabolism , Cells, Cultured , DNA/drug effects , DNA/metabolism , Dimerization , Endothelium, Vascular/metabolism , Humans , I-kappa B Proteins/metabolism , Ligases/metabolism , NF-kappa B/genetics , Transcription Factors/drug effects , Transcription Factors/metabolism , Transcription, Genetic/drug effects , Tumor Necrosis Factor-alpha/metabolism
15.
J Biol Chem ; 277(29): 26460-7, 2002 Jul 19.
Article in English | MEDLINE | ID: mdl-12006557

ABSTRACT

Interferon (IFN)-gamma facilitates cellular immune response, in part, by inducing the expression of major histocompatibility complex class II (MHC-II) molecules. We demonstrate that IFN-gamma induces the expression of HLA-DRA in vascular endothelial cells via mechanisms involving reactive oxygen species. IFN-gamma-induced HLA-DRA expression was inhibited by nitric oxide (NO) and antioxidants such as superoxide dismutase, catalase, pyrrolidine dithiocarbamate, and N-acetylcysteine. Nuclear run-on assays demonstrated that NO and antioxidants inhibited IFN-gamma-induced HLA-DRA gene transcription. Transient transfection studies using a fully functional HLA-DRA promoter construct ([-300]DR alpha.CAT) showed that inhibition of endogenous NO synthase activity by N(omega)-monomethyl-l-arginine or addition of exogenous hydrogen peroxide (H(2)O(2)) augmented basal and IFN-gamma-stimulated [-300]DR alpha.CAT activity. However, H(2)O(2) and N(omega)-monomethyl-l-arginine could induce HLA-DRA expression suggesting that H(2)O(2) is a necessary but not a sufficient mediator of IFN-gamma-induced HLA-DRA expression. Electrophoretic mobility shift assay and Western blotting demonstrated that NO and antioxidants had little or no effect on IFN-gamma-induced IRF-1 activation or MHC-II transactivator (CIITA) expression but did inhibit IFN-gamma-induced activation of STAT1 alpha (p91) and Y box transcription factors, NF-Y(A) and NF-Y(B). These results indicate that NO and antioxidants may attenuate vascular inflammation by antagonizing the effects of intracellular reactive oxygen species generation by IFN-gamma, which is necessary for MHC-II gene transcription.


Subject(s)
Antioxidants/pharmacology , Genes, MHC Class II/drug effects , Nitric Oxide/pharmacology , Oxidative Stress/genetics , Transcription, Genetic/drug effects , Blotting, Northern , Blotting, Western , Cells, Cultured , Endothelium, Vascular/drug effects , Endothelium, Vascular/metabolism , HLA-DR Antigens/genetics , HLA-DR alpha-Chains , Humans , Hydrogen Peroxide/pharmacology , Interferon-gamma/pharmacology , Oxidation-Reduction , Promoter Regions, Genetic , RNA, Messenger/metabolism , Reactive Oxygen Species/metabolism , Transfection , omega-N-Methylarginine/pharmacology
16.
Mol Pharmacol ; 61(4): 840-52, 2002 Apr.
Article in English | MEDLINE | ID: mdl-11901223

ABSTRACT

CYP2J2 is abundant in cardiovascular tissue and active in the metabolism of arachidonic acid to eicosanoids that possess potent anti-inflammatory, vasodilatory, and fibrinolytic properties. We cloned and sequenced the entire CYP2J2 gene (approximately 40.3 kb), which contains nine exons and eight introns. We then sequenced the CYP2J2 exons and intron-exon boundaries in 72 healthy persons representing African, Asian, and European/white populations as part of the National Institutes of Health/National Institute of Environmental Health Sciences Environmental Genome Single Nucleotide Polymorphism Program. A variety of polymorphisms were found, four of which resulted in coding changes (Arg158Cys, Ile192Asn, Asp342Asn, and Asn404Tyr). A fifth variant (Thr143Ala) was identified by screening a human heart cDNA library. All five variant cDNAs of CYP2J2 were generated by site-directed mutagenesis and expressed in Sf9 insect cells by using a baculovirus system. The recombinant wild-type and variant CYP2J2 proteins immunoreacted with peptide-based antibodies to CYP2J2 and displayed typical cytochrome P450 (P450) CO-difference spectra; however, the Asn404Tyr and Ile192Asn variants also had prominent spectral peaks at 420 nm. The ability of these variants to metabolize arachidonic acid and linoleic acid was compared with that of wild-type CYP2J2. Three variants (Asn404Tyr, Arg158Cys, and Thr143Ala) showed significantly reduced metabolism of both arachidonic acid and linoleic acid. The Ile192Asn variant showed significantly reduced activity toward arachidonic acid only. The Asp342Asn variant showed similar metabolism to wild-type CYP2J2 for both endogenous substrates. Based on these data, we conclude that allelic variants of the human CYP2J2 gene exist and that some of these variants result in a P450 protein that has reduced catalytic function. Insofar as CYP2J2 products have effects in the cardiovascular system, we speculate that these variants may be functionally relevant.


Subject(s)
Cytochrome P-450 Enzyme System/genetics , Oxygenases/genetics , Polymorphism, Genetic , Alleles , Arachidonic Acid/metabolism , Cloning, Molecular , Cytochrome P-450 CYP2J2 , DNA, Complementary/analysis , Exons , Gene Expression , Genome, Human , Humans , Introns , Linoleic Acid/metabolism , Molecular Sequence Data , Recombinant Proteins/metabolism , Sequence Analysis, DNA , Transcription, Genetic
SELECTION OF CITATIONS
SEARCH DETAIL
...